Bacterial Contig Map of the 21q11 Region Associated with Alzheimer’s Disease and Abnormal Myelopoiesis in Down Syndrome
- Jürgen Groet1,
- Jane H. Ives1,
- Andrew P. South1,
- Pedro R. Baptista1,
- Tania A. Jones2,
- Marie-Laure Yaspo3,
- Hans Lehrach3,
- Marie-Claude Potier4,
- Christine Van Broeckhoven5, and
- Dean Nižetić1,6
- 1Centre for Applied Molecular Biology, School of Pharmacy, University of London, London WC1N 1AX, UK; 2Human Cytogenetics Laboratory, Imperial Cancer Research Fund, London WC2A 3PX, UK; 3Max-Planck-Institute for Human Genetics, Berlin-Dahlem, Germany; 4Neurobiology Laboratory, Centre National de la Recherche Scientifique URA 2054, 75005 Paris, France; 5Laboratory of Neurogenetics, Flanders Interuniversity Institute for Biotechnology (VIB), Born Bunge Foundation (BBS), University of Antwerp (UIA), Department of Biochemistry, Antwerp, Belgium
Abstract
We present a high-resolution bacterial contig map of 3.4 Mb of genomic DNA in human chromosome 21q11–q21, encompassing the region of elevated disomic homozygosity in Down Syndrome-associated abnormal myelopoiesis and leukemia, as well as the markers, which has shown a strong association with Alzheimer’s Disease that has never been explained. The map contains 89 overlapping PACs, BACs, or cosmids in three contigs (850, 850, and 1500 kb) with two gaps (one of 140–210 kb and the second <5 kb). To date, eight transcribed sequences derived by cDNA selection, exon trapping, and/or global EST sequencing have been positioned onto the map, and the only two genes so far mapped to this cytogenetic region, STCH and RIP140 have been precisely localized. This work converts a further 10% of chromosome 21q into a high-resolution bacterial contig map, which will be the physical basis for the long-range sequencing of this region. The map will also enable positional derivation of new transcribed sequences, as well as new polymorphic probes, that will help in elucidation of the role the genes in this region may play in abnormal myelopoiesis and leukemia associated with trisomy 21 and Alzheimer’s Disease.
Footnotes
-
↵6 Corresponding author.
-
E-MAIL dnizet{at}pharm.lon.ac.uk; FAX 44-171-278 1939.
-
- Received August 4, 1997.
- Accepted February 19, 1998.
- Cold Spring Harbor Laboratory Press











